modelInsulinGlargine
Extends from Pharmacolibrary.Drugs.ATC.A.A10AE04.
Information
| name: | InsulinGlargine | |
| ATC code: | A10AE04 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 0.4 | mg |
| volume of distribution: | 0.1 | L |
| clearance: | 0.045 | L/h/kg |
| other parameters in model implementation | ||
Insulin glargine is a long-acting insulin analog used to improve glycemic control in adults and children with diabetes mellitus. It is administered subcutaneously and provides a prolonged, relatively constant level of insulin activity. Insulin glargine is currently approved and widely used in clinical practice.
Pharmacokinetics
Pharmacokinetics in adult healthy volunteers and patients with diabetes (both type 1 and type 2); following subcutaneous administration.
References
Faggionato, E, et al., & Man, CD (2021). Modeling Between-Subject Variability in Subcutaneous Absorption of a Long-Acting Insulin Glargine 100 U/mL by a Nonlinear Mixed Effects Approach. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2021 4226–4229. DOI:10.1109/EMBC46164.2021.9629554 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34892156
Hurren, KM, & O'Neill, JL (2016). Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes. Expert opinion on drug metabolism & toxicology 12(12) 1521–1526. DOI:10.1080/17425255.2016.1245722 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27710135
Rendell, M (2013). Insulin degludec: a long-acting modern insulin analogue with a predictable pharmacokinetic/pharmacodynamic profile. Drugs of today (Barcelona, Spain : 1998) 49(6) 387–397. DOI:10.1358/dot.2013.49.6.1976051 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23807942
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)